profit from every $100 of sales.
$0$100
Galectin Therapeutics
$3.05-2.87% today
-44.8% in 1 year
1-year low $2.081-year high $6.51
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Galectin Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$30.8 million of profit last year.
SalesProfit
Galectin Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Galectin Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Galectin Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -38 | -38 | -42 | -20 | |
| -38 | -38 | -41 | -23 | |
| -39 | -41 | -47 | -31 | |
| -0.65 | -0.74 | -0.76 | -0.48 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 21 | 28 | 17 | 20 |
| Cash | 19 | 26 | 15 | 18 |
| Total debt | 40 | 72 | 106 | 134 |
| Total liabilities | 53 | 88 | 121 | 146 |
| -32 | -60 | -103 | -126 | |
| 59 | 60 | 62 | 64 | |
| -388.5% | -261.9% | -1,032.8% | -245.6% | |
| 120.4% | 68.2% | 45.6% | 24.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -31 | -33 | -42 | -24 | |
| – | – | – | – | |
| -31 | -33 | -42 | -24 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 2 | 2 | 2 |
Valuation
- –
- –
- –
- -1.1×
- –
- –
- –
- -7.8%
- -10.0%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -192.3%
- -569.5%
- 21.0%
- -166.6%
- -192.4%
- –
Growth
- –
- –
- +42.8%
- –
- +2.2%
Financial health
- -6.2×
- -1.04
- 861.2%
- -2.1×
- 2.15
- 2.15
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 884
Bottom 12%of 987
What analysts expect
- Average price target
- $11.00
- Range
- $11.00 – $11.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 15, 2026 | -0.08 | -0.06 | −33.3% |
| Mar 31, 2026 | -0.08 | -0.10 | +20.0% |
| Nov 14, 2025 | -0.13 | -0.11 | −18.2% |
| Aug 14, 2025 | -0.12 | -0.16 | +25.0% |
| May 15, 2025 | -0.15 | -0.20 | +25.0% |
| Mar 31, 2025 | -0.19 | -0.16 | −18.8% |
| Nov 14, 2024 | -0.18 | -0.20 | +10.0% |
| Aug 13, 2024 | -0.20 | -0.16 | −25.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
28No pass
Philip Fisher
35No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
26No pass
Questions about Galectin Therapeutics
Is Galectin Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Galectin Therapeutics AI analysis
What does Galectin Therapeutics do?
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. It is in Biotechnology.
Does Galectin Therapeutics pay a dividend?
No. Galectin Therapeutics does not pay a dividend at the moment.
Is Galectin Therapeutics stock halal?
No. Galectin Therapeutics does not pass our halal screen: its debt is 44% of its market value, at or above the 33% limit. How we check
How has Galectin Therapeutics stock done over the past year?
Down 44.8% over the past twelve months, to $3.05. It traded between $2.08 and $6.51 and is 53.1% below its high.
Who are Galectin Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Galectin Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.